Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Pā¦ (NCT07509645) | Clinical Trial Compass
RecruitingPhase 3
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
China348 participantsStarted 2026-04-22
Plain-language summary
This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Age 18 years or older, of either sex;
ā. Acute ischemic stroke caused by occlusion of the basilar artery;
ā. Decide to undergo emergency endovascular treatment;
ā. Time from stroke onset to groin puncture within 24 hours;
ā. National Institutes of Health Stroke Scale (NIHSS) ā„ 10;
ā. Posterior circulation Alberta Stroke Program Early computed tomography score (pc-ASPECTS) ā„ 6;
ā. Signed informed consent from the patients or the legally authorized representatives.